BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Genetix Biotherapeutics Inc. (formerly bluebird bio\, Inc.) re
 adouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Genetix Biotherapeutics Inc. (for
 merly bluebird bio\, Inc.)'s drugs run\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04293185-10297@assetmemo.bio
DTSTAMP:20261121T011244Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lovotibeglogene autotemcel (Lyfgenia): Phase 3 readout est. (NCT042
 93185)
DESCRIPTION:Lovotibeglogene autotemcel (Lyfgenia)\, phase 3\, Sickle Cell D
 isease.\nStudy: A Study Evaluating Gene Therapy With BB305 Lentiviral Vect
 or in Sickle Cell Disease\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lovotibeglogene-autotemcel-l
 yfgenia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04293185
URL:https://assetmemo.bio/drug/lovotibeglogene-autotemcel-lyfgenia#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
